Literature DB >> 7544570

Biochemical characteristics and clinical applications of alpha-fetoprotein isoforms.

E Seregni1, C Botti, E Bombardieri.   

Abstract

Alphafetoprotein (AFP) is an oncofetal glycoprotein that frequently reappears in sera of patients affected by hepatocellular carcinoma (HCC) and yolk-sac tumours (YST). In these cases AFP determination represents a useful marker for monitoring the therapeutic response and the clinical evolution of the neoplastic disease. AFP is a heterogeneous molecule with respect to the carbohydrate moiety and the different AFP glycoforms can be separated and characterized by their affinity for lectins, such as Concanavalin A (con A), and Lens culinaris agglutinin (LCA). Increased production of LCA-reactive AFP has been proposed as a specific and early marker for HCC, while Con A non-reactive AFP could be a marker for YST and gastrointestinal malignancies. In this review the molecular basis of AFP microheterogeneity and the clinical application of AFP isoforms will be discussed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7544570

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

1.  Alpha-fetoprotein in canine multicentric lymphoma.

Authors:  R Lechowski; D Jagielski; M Hoffmann-Jagielska; M Zmudzka; A Winnicka
Journal:  Vet Res Commun       Date:  2002-06       Impact factor: 2.459

2.  AFP-producing acinar cell carcinoma treated by pancreaticoduodenectomy in a patient with a previous radical subtotal gastrectomy by gastric cancer.

Authors:  Chang Young Kim; Sung Hwan Lee; Hyae Min Jeon; Hyun Ki Kim; Chang Moo Kang; Woo Jung Lee
Journal:  Korean J Hepatobiliary Pancreat Surg       Date:  2014-02-24

Review 3.  Circulating predictive and diagnostic biomarkers for hepatitis B virus-associated hepatocellular carcinoma.

Authors:  Stijn Van Hees; Peter Michielsen; Thomas Vanwolleghem
Journal:  World J Gastroenterol       Date:  2016-10-07       Impact factor: 5.742

4.  Plasma Heat Shock Protein 90alpha as a Biomarker for the Diagnosis of Liver Cancer: An Official, Large-scale, and Multicenter Clinical Trial.

Authors:  Yan Fu; Xiao Xu; Dongsheng Huang; Dawei Cui; Lisheng Liu; Junwei Liu; Zenglei He; Jingjing Liu; Shusen Zheng; Yongzhang Luo
Journal:  EBioMedicine       Date:  2017-09-12       Impact factor: 8.143

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.